BACKGROUND: Infection with the human T-cell lymphotropic virus, type 1 (HTLV-1) has been associated with an increased Th1 response. Interestingly, a higher prevalence of helminthic coinfection has been observed among infected individuals, and subsequent modulation of the immune response typically associated with helminths may influence clinical outcomes among HTLV-1 coinfected individuals. OBJECTIVE: This study was conducted to elucidate the association between helminthic coinfection and the development of clinically characterized neurologic disease that occurs in HTLV-1 infection. STUDY DESIGN: In a cohort analysis, incidence of HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP) was recorded. Incidence of clinical outcomes and disease-free survival of several neurologic outcomes associated with HTLV-1 were estimated using the Kaplan-Meier method with log-rank tests. The relationships between helminthic infection and risk of HTLV-1 neurologic outcomes were assessed by Cox proportional hazard modeling. RESULTS: Seventy-four coinfected and 79 non-coinfected patients were followed, with 92 helminthic infections observed in the coinfected group. One patient per group developed HAM/TSP and the risk of progression to neurologic disease outcomes did not differ among those with and without helminthic coinfection (p>0.45). A significant difference was noted in the prevalence of neurologic disease outcomes among all patients at the conclusion of the study (p<0.01). CONCLUSIONS: These data suggest that treated helminthic infection does not affect risk of development of neurologic disease in HTLV-1 infection, and reinforce that treatment of helminths does not adversely affect patients with HTLV-1. Importantly, among all patients, an overall progression of neurologic disease was observed. Copyright Â
BACKGROUND:Infection with the human T-cell lymphotropic virus, type 1 (HTLV-1) has been associated with an increased Th1 response. Interestingly, a higher prevalence of helminthic coinfection has been observed among infected individuals, and subsequent modulation of the immune response typically associated with helminths may influence clinical outcomes among HTLV-1 coinfected individuals. OBJECTIVE: This study was conducted to elucidate the association between helminthic coinfection and the development of clinically characterized neurologic disease that occurs in HTLV-1 infection. STUDY DESIGN: In a cohort analysis, incidence of HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP) was recorded. Incidence of clinical outcomes and disease-free survival of several neurologic outcomes associated with HTLV-1 were estimated using the Kaplan-Meier method with log-rank tests. The relationships between helminthic infection and risk of HTLV-1 neurologic outcomes were assessed by Cox proportional hazard modeling. RESULTS: Seventy-four coinfected and 79 non-coinfected patients were followed, with 92 helminthic infections observed in the coinfected group. One patient per group developed HAM/TSP and the risk of progression to neurologic disease outcomes did not differ among those with and without helminthic coinfection (p>0.45). A significant difference was noted in the prevalence of neurologic disease outcomes among all patients at the conclusion of the study (p<0.01). CONCLUSIONS: These data suggest that treated helminthic infection does not affect risk of development of neurologic disease in HTLV-1 infection, and reinforce that treatment of helminths does not adversely affect patients with HTLV-1. Importantly, among all patients, an overall progression of neurologic disease was observed. Copyright Â
Authors: A Krämer; S Jacobson; J F Reuben; E L Murphy; S Z Wiktor; B Cranston; J P Figueroa; B Hanchard; D McFarlin; W A Blattner Journal: Lancet Date: 1989-10-14 Impact factor: 79.321
Authors: Robert W Summers; David E Elliott; Khurram Qadir; Joseph F Urban; Robin Thompson; Joel V Weinstock Journal: Am J Gastroenterol Date: 2003-09 Impact factor: 10.864
Authors: Ana C C Leite; Marcus Tulius T Silva; Alexandre H Alamy; Cristiane R A Afonso; Marco A D Lima; Maria J Andrada-Serpa; Osvaldo J M Nascimento; Abelardo Q-C Araújo Journal: J Neurol Date: 2004-07 Impact factor: 4.849
Authors: Peter K C Goon; Tadahiko Igakura; Emmanuel Hanon; Angelina J Mosley; Becca Asquith; Keith G Gould; Graham P Taylor; Jonathan N Weber; Charles R M Bangham Journal: J Virol Date: 2003-09 Impact factor: 5.103
Authors: A F Porto; S B Santos; L Alcantara; J B Guerreiro; J Passos; T Gonzalez; F Neva; D Gonzalez; J L Ho; E M Carvalho Journal: Clin Exp Immunol Date: 2004-08 Impact factor: 4.330